|
US4275149A
(en)
|
1978-11-24 |
1981-06-23 |
Syva Company |
Macromolecular environment control in specific receptor assays
|
|
US4318980A
(en)
|
1978-04-10 |
1982-03-09 |
Miles Laboratories, Inc. |
Heterogenous specific binding assay employing a cycling reactant as label
|
|
US4424200A
(en)
|
1979-05-14 |
1984-01-03 |
Nuc Med Inc. |
Method for radiolabeling proteins with technetium-99m
|
|
US4479930A
(en)
|
1982-07-26 |
1984-10-30 |
Trustees Of The University Of Massachusetts |
Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
US5185243A
(en)
|
1988-08-25 |
1993-02-09 |
Syntex (U.S.A.) Inc. |
Method for detection of specific nucleic acid sequences
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
DK0617706T3
(da)
|
1991-11-25 |
2001-11-12 |
Enzon Inc |
Multivalente antigenbindende proteiner
|
|
CA2150262C
(en)
|
1992-12-04 |
2008-07-08 |
Kaspar-Philipp Holliger |
Multivalent and multispecific binding proteins, their manufacture and use
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9509957D0
(en)
|
1995-05-17 |
1995-07-12 |
Khalil Nasreen |
Post-translational activation of tgf-1 involving the tsp-1 receptor cd36
|
|
US5814468A
(en)
|
1996-03-27 |
1998-09-29 |
Coulter International Corp. |
Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
|
|
US5958671A
(en)
|
1996-04-23 |
1999-09-28 |
Presidents And Fellows Of Harvard College |
Methods and compositions for regulating T cell subsets by modulating transcription factor activity
|
|
JP2002509431A
(ja)
|
1996-12-23 |
2002-03-26 |
イミュネックス・コーポレーション |
ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
|
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
|
US6274338B1
(en)
*
|
1998-02-24 |
2001-08-14 |
President And Fellows Of Harvard College |
Human c-Maf compositions and methods of use thereof
|
|
ATE439592T1
(de)
|
1998-12-10 |
2009-08-15 |
Bristol Myers Squibb Co |
Proteingerüste für antikörper-nachahmer und andere bindende proteine
|
|
ES2215626T3
(es)
|
1999-03-15 |
2004-10-16 |
Axys Pharmaceuticals, Inc. |
N-cianomethil amidas como inhibidores de proteasas.
|
|
CA2396257A1
(en)
|
2000-01-06 |
2001-07-12 |
Merck Frosst Canada & Co./Merck Frosst Canada & Cie |
Novel compounds and compositions as protease inhibitors
|
|
DE60126592T2
(de)
|
2000-04-03 |
2007-11-22 |
Corixa Corp., Hamilton |
Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
|
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
|
MY143582A
(en)
|
2001-06-26 |
2011-05-31 |
Amgent Fremont Inc |
Antibodies to opgl
|
|
WO2004006955A1
(en)
|
2001-07-12 |
2004-01-22 |
Jefferson Foote |
Super humanized antibodies
|
|
AR036375A1
(es)
|
2001-08-30 |
2004-09-01 |
Novartis Ag |
Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
|
|
GB0121033D0
(en)
|
2001-08-30 |
2001-10-24 |
Novartis Ag |
Organic compounds
|
|
JP4238138B2
(ja)
|
2001-12-22 |
2009-03-11 |
４−アンチボディ アーゲー |
遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。
|
|
SE0201980D0
(sv)
|
2002-06-24 |
2002-06-24 |
Astrazeneca Ab |
Novel compounds
|
|
WO2005046731A1
(en)
|
2003-10-17 |
2005-05-26 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Interference with c-maf function in multiple myeloma
|
|
US20090048117A1
(en)
|
2003-12-18 |
2009-02-19 |
President And Fellows Of Harvard College |
Modulation of immune system function by modulation of polypeptide arginine methyltransferases
|
|
JP5457673B2
(ja)
|
2005-09-20 |
2014-04-02 |
ベリデックス・リミテッド・ライアビリティ・カンパニー |
ユニーク配列のｄｎａプローブを作製するための方法および組成物、ｄｎａプローブの標識、ならびにこれらプローブの使用
|
|
US9134237B2
(en)
|
2005-09-20 |
2015-09-15 |
Janssen Diagnotics, LLC |
High sensitivity multiparameter method for rare event analysis in a biological sample
|
|
EP1777523A1
(en)
|
2005-10-19 |
2007-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
|
|
US8785150B2
(en)
|
2006-06-30 |
2014-07-22 |
University Of Southern California |
Quantifiable internal reference standards for immunohistochemistry and uses thereof
|
|
WO2008086800A2
(en)
|
2007-01-15 |
2008-07-24 |
Aarhus Universitet |
Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16
|
|
WO2008098351A1
(en)
|
2007-02-14 |
2008-08-21 |
University Health Network |
Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
|
|
AU2008244648A1
(en)
|
2007-02-16 |
2008-11-06 |
Pacific Arrow Limited |
Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
|
|
RU2481355C2
(ru)
|
2007-05-24 |
2013-05-10 |
Аблинкс Н.В. |
Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей
|
|
WO2010003773A1
(en)
|
2008-06-16 |
2010-01-14 |
Siemens Medical Solutions Diagnostics Gmbh |
Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
|
|
JPWO2010110346A1
(ja)
|
2009-03-24 |
2012-10-04 |
独立行政法人理化学研究所 |
白血病幹細胞マーカー
|
|
WO2011039734A2
(en)
|
2009-10-02 |
2011-04-07 |
Enzo Medico |
Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
|
|
ES2562274T3
(es)
|
2010-10-06 |
2016-03-03 |
Fundació Institut De Recerca Biomèdica (Irb Barcelona) |
Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
|
|
WO2012106718A2
(en)
|
2011-02-04 |
2012-08-09 |
Bioarray Therapeutics, Inc. |
Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
|
|
EP2650682A1
(en)
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Method for the prognosis and treatment of cancer metastasis
|
|
BR112014030750A2
(pt)
|
2012-06-06 |
2017-08-22 |
Inst Catalana Recerca Estudis Avancats |
Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
|
|
US10119171B2
(en)
|
2012-10-12 |
2018-11-06 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
|
HK1213946A1
(zh)
|
2012-10-12 |
2016-07-15 |
Inbiomotion S.L. |
用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
|
|
CN105324491B
(zh)
|
2013-03-15 |
2021-10-26 |
生物医学研究机构基金会 |
用于癌症转移的诊断和治疗的方法
|
|
WO2014184679A2
(en)
|
2013-03-15 |
2014-11-20 |
Inbiomotion S.L. |
Method for the prognosis and treatment of renal cell carcinoma metastasis
|
|
AU2014229563B2
(en)
|
2013-03-15 |
2020-04-09 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the diagnosis, prognosis and treatment of cancer metastasis
|
|
EP3055429B1
(en)
|
2013-10-09 |
2019-03-27 |
Fundació Institut de Recerca Biomèdica (IRB Barcelona) |
Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
|
|
CA2967224C
(en)
|
2014-12-11 |
2023-08-22 |
Inbiomotion S.L. |
Binding members for human c-maf
|
|
PL3458610T3
(pl)
|
2016-05-25 |
2021-11-22 |
Inbiomotion S.L. |
Leczenie raka piersi w oparciu o status c-MAF
|
|
JP2021504339A
(ja)
|
2017-11-22 |
2021-02-15 |
インバイオモーション エセ．エレ． |
ｃ−ＭＡＦの状態に基づく乳がんの治療的処置
|